RPA2 is altered in 2.13% of breast carcinoma patients [3].

RPA2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is altered in 0.27% of malignant solid tumor patients [3].

RPA2 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RPA2 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].